Revibe Technologies
Revibe Technologies is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Revibe Technologies.
Revibe Technologies is a company.
Key people at Revibe Technologies.
Revibe Technologies is a digital therapeutics company developing wearable technology to treat attention and focus challenges, primarily for ADHD and Autism in children and adults.[1][2][3] It builds Software as a Medical Device (SaMD) integrated into smartwatches, like Samsung hardware, that deliver personalized vibration and text reminders to enhance self-regulation, while collecting behavioral data via AI and machine learning for actionable insights.[1][4][6] The product serves students, professionals, clinicians, educators, and caregivers facing classroom or workplace distractions, solving inattention through subtle, non-pharmacological cues that track metrics like focus span, fidgeting, and activity to improve outcomes and adherence.[3][5][6] With over 40,000 units sold as an OTC product and nominations like the 2023 Prix Galien Award, Revibe shows growth via partnerships (e.g., Pearson Assessments) and funding from investors like The Launch Place and RTP Capital Associates.[1][2][6]
Founded in 2013 in Wake Forest, North Carolina, by school psychologist Rich Brancaccio, Revibe emerged from his observations of students struggling with focus and attention in classrooms.[1][3][6] Brancaccio, as Chief Innovation Officer, fused psychology with technology to create a wearable tool leveling the playing field for kids with ADHD-like challenges; the company was formerly FokusLabs Behavioral Solutions.[1][3] Joseph Koziak serves as CEO, bringing expertise in financing and commercializing digital therapeutics.[1][2] Early traction included selling over 40,000 OTC wearable units, amassing 10 million hours of user data, which informed pivots to regulated SaMD for ADHD, Autism, and CNS conditions, with presentations at events like CNS Summit 2021.[2][4]
Revibe rides the digital therapeutics and wearable healthtech wave, targeting the growing ADHD/Autism market amid rising neurological disorder diagnoses and demand for non-pharmacological alternatives.[1][2] Timing aligns with AI advancements in personalized medicine and post-pandemic focus on mental health, where wearables enable remote monitoring and data scalability.[4][6] Market forces like regulatory nods for SaMD, investor interest in CNS solutions, and clinician adoption (e.g., via Pearson) favor expansion; Revibe influences the ecosystem by validating AI-wearables for behavioral health, potentially extending to other conditions and setting standards for data privacy in youth-focused tech.[1][2][6]
Revibe is poised to scale its SaMD platform through FDA pathways, deeper clinician integrations, and data monetization from its vast dataset, targeting ADHD/Autism dominance before broader CNS applications.[1][2][4] Trends like AI personalization, wearable ubiquity, and value-based care will accelerate growth, evolving its influence from niche educator tool to mainstream therapeutic standard. As digital health matures, Revibe's psych-tech fusion could redefine focus management, building on its foundational traction to transform lives in classrooms and beyond.[1][3][6]
Key people at Revibe Technologies.